Merck & Co dented by Januvia labeling denial

7 April 2017

Shares in US pharma giant Merck & Co (NYSE: MRK) slipped in the morning’s trading on news that the US Food and Drug Administration (FDA) had issued a Complete Response Letter regarding the company’s Supplemental New Drug Applications for Januvia (sitagliptin) and its two Janumet (sitagliptin and metformin HCl) formulations.

Merck & Co had sought through these applications to include data from the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) study, in the prescribing information of sitagliptin-containing medicines, with the study showing that their use did not raise the risk of cardiovascular complications among treated patients. They are prescribed for type 2 diabetes.

Januvia/Janumet was by far the company’s biggest selling product last year, raising $6.11 billion, and Merck had wanted this addition to the label to help distinguish themselves from rival drugs such as Onglyza (saxagliptin), a treatment marketed by Anglo-Swedish pharma major AstraZeneca (LSE: AZN) which has been linked to safety risks.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK